208 related articles for article (PubMed ID: 8222099)
21. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
Circulation; 1994 Oct; 90(4):1631-7. PubMed ID: 7923645
[TBL] [Abstract][Full Text] [Related]
23. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Yusuf S
Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
[TBL] [Abstract][Full Text] [Related]
24. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
[TBL] [Abstract][Full Text] [Related]
25. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
26. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
Kastrati A; Neumann FJ; Schulz S; Massberg S; Byrne RA; Ferenc M; Laugwitz KL; Pache J; Ott I; Hausleiter J; Seyfarth M; Gick M; Antoniucci D; Schömig A; Berger PB; Mehilli J;
N Engl J Med; 2011 Nov; 365(21):1980-9. PubMed ID: 22077909
[TBL] [Abstract][Full Text] [Related]
27. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.
Zoldhelyi P; Webster MW; Fuster V; Grill DE; Gaspar D; Edwards SJ; Cabot CF; Chesebro JH
Circulation; 1993 Nov; 88(5 Pt 1):2015-22. PubMed ID: 8222093
[TBL] [Abstract][Full Text] [Related]
28. The role of recombinant hirudins in the management of thrombotic disorders.
Fischer KG
BioDrugs; 2004; 18(4):235-68. PubMed ID: 15244501
[TBL] [Abstract][Full Text] [Related]
29. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
30. Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty.
Bonello L; de Labriolle A; Roy P; Steinberg DH; Pinto Slottow TL; Xue Z; Kaneshige K; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2009; 10(3):156-61. PubMed ID: 19595396
[TBL] [Abstract][Full Text] [Related]
31. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
[TBL] [Abstract][Full Text] [Related]
32. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.
Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators
N Engl J Med; 1996 Sep; 335(11):775-82. PubMed ID: 8778585
[TBL] [Abstract][Full Text] [Related]
33. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
Antman EM
Circulation; 1996 Sep; 94(5):911-21. PubMed ID: 8790025
[TBL] [Abstract][Full Text] [Related]
34. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial.
Schächinger V; Allert M; Kasper W; Just H; Vach W; Zeiher AM
Circulation; 1994 Nov; 90(5):2258-66. PubMed ID: 7955182
[TBL] [Abstract][Full Text] [Related]
35. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
Campbell KR; Mahaffey KW; Lewis BE; Weitz JI; Berkowitz SD; Ohman EM; Califf RM
J Invasive Cardiol; 2000 Dec; 12 Suppl F():14F-9. PubMed ID: 11156729
[No Abstract] [Full Text] [Related]
36. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
[TBL] [Abstract][Full Text] [Related]
37. Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina.
Borries M; Heins M; Fischer Y; Stiegler H; Peters A; Reinauer H; Schoebel FC; Strauer BE; Leschke M
J Am Coll Cardiol; 1999 Aug; 34(2):486-93. PubMed ID: 10440163
[TBL] [Abstract][Full Text] [Related]
38. Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention.
Roe MT; Granger CB; Puma JA; Hellkamp AS; Hochman JS; Ohman EM; White HD; Van de Werf F; Armstrong PW; Ellis SG; Califf RM; Topol EJ
Am J Cardiol; 2001 Dec; 88(12):1403-6, A6. PubMed ID: 11741559
[No Abstract] [Full Text] [Related]
39. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
Eriksson BI; Ekman S; Kalebo P; Zachrisson B; Bach D; Close P
Lancet; 1996 Mar; 347(9002):635-9. PubMed ID: 8596376
[TBL] [Abstract][Full Text] [Related]
40. Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
Lincoff AM
Am Heart J; 2003 Oct; 146(4 Suppl):S23-30. PubMed ID: 14564303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
